Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: A report from the Children's Oncology Group

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 516-522

  Johansen, Mary ^a   Kuttesch, John ^a   Bleyer, W Archie ^a   Krailo, Mark ^b   Ames, Matthew ^c   Madden, Timothy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; NAVELBINE; UREA; VINCA ALKALOID;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; ARTICLE; ASTROCYTOMA; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DISTRIBUTION; DRUG SAFETY; EWING SARCOMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATURIA; HEPATOSPLENOMEGALY; HUMAN; HYPERBILIRUBINEMIA; INJECTION SITE PHLEBITIS; LEUKOPENIA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MENINGIOMA; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TACHYPNEA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; UREA NITROGEN BLOOD LEVEL; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BONE NEOPLASMS; CAPSULES; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GELATIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; SARCOMA; VINBLASTINE;

EID: 31544481209     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1541     Document Type: Article

References (21)

1. Takasugi BJ, Jones SE, Robertone AB. Phase II trial of vinzolidine, an oral Vinca alkaloid in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer Treat Rep 1984;68:1399-401.
2. Budman DR, Schulman P, Marks M, et al. Phase I trial of vinzolidine. Cancer Treat Rep 1984;68:979-82.
3. Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J. Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum. Cancer Chemother Pharmacol 1985;14:12-4.
4. Tortoriello A, Facchini G, Caponigro F, et al. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998;47:91-7.
5. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC). Semin Oncol 1989;16:26-9.
6. Winer EP, Chu L, Spicer DV. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. Semin Oncol 1995;22:72-9.
7. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:1346-50.
8. Palmeri S, Leonardi V, Gebbia V, et al. Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer 2001;34:115-23.
9. Canobbio L, Boccardo F, Pastorino G, et al. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol 1989;16:33-6.
10. Hanley ML, Elion GB, Colvin OM, et al. Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother Pharmacol 1998;42:479-82.
11. Fellous A, Ohayan R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 1989;16:9-14.
12. Ngan VK, Bellman K, Hill BT, Wilson L, Jordan MA. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol 2001;60:225-32.
13. 3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. Anticancer Drugs 1991;2:405-10.
14. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 1994;12:1754-63.
15. Rowinsky EK, Lucas VS, Hsieh AL, et al. The effects of food and divided dosing on the bioavailability of oral vinorelbine. Cancer Chemother Pharmacol 1996;39:9-16.
16. Mathe G, Reizenstein P. Phase I pharmacologic study of a new Vinca alkaloid: Navelbine. Cancer Lett 1985;27:285-93.
17. Schilling T, Fiebig HH, Kerpel-Fronius S, et al. Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs 1996;14:371-8.
18. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res 1991;51:2073-6.
19. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992;42:545-7.
20. Sabot C, Marquet P, Debord J, Carpentier N, Merle L, Lachatre G. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Clin Pharmacol 1998;54:171-5.
21. Zhou XJ, Bore P, Monjanel S, et al. Pharmacokinetics of navelbine after oral administration in cancer patients. Cancer Chemother Pharmacol 1991;29:66-70.